Fig. 1
From: Ιmpact of sunitinib-induced hypothyroidism on survival of patients with metastatic renal cancer
Response to treatment. In our cohort the median PFS was 9.47 months and the median OS was 22.03 months. Our data are consistent with published data by other authors. The median follow-up of our patients was 19.2 months